Table 4.

Adjusted associations of the presence of tumor cell or diffuse tumor vasculature B7-H3 expression with death from RCC for 743 ccRCC patients

Feature	Risk ratio (95% CI)*	P
Age at surgery	3.08 (2.36-4.03)	<0.001
Gender	3.10 (2.37-4.05)	<0.001
Symptoms at presentation	2.84 (2.17-3.72)	<0.001
Constitutional symptoms at presentation	2.73 (2.07-3.60)	<0.001
ECOG performance status	3.08 (2.36-4.03)	<0.001
Tumor thrombus	2.68 (2.04-3.53)	<0.001
Primary tumor size	2.32 (1.77-3.04)	<0.001
2002 Primary tumor classification	2.17 (1.65-2.85)	<0.001
Regional lymph node involvement	3.01 (2.30-3.93)	<0.001
Distant metastases	2.72 (2.07-3.56)	<0.001
2002 TNM stage groupings	2.25 (1.71-2.96)	<0.001
Nuclear grade	1.78 (1.34-2.36)	0.003
Coagulative tumor necrosis	1.75 (1.31-2.34)	<0.001
Sarcomatoid Differentiation	2.74 (2.08-3.60)	<0.001
TNM stage groupings, nuclear grade, ECOG	1.68 (1.27-2.24)	<0.001
SSIGN score	1.38 (1.03-1.84)	0.029

^*Risk ratio represents the association of the presence of positive tumor cell or diffuse tumor vasculature B7-H3 expression with death from RCC (using negative tumor cell and absent, focal, or moderate tumor vasculature B7-H3 expression as the reference group) after adjustment for the feature or combination of features listed.